This inventor holds 4 USPTO granted patents and 4 published patent applications. Top assignees: Amylin Pharmaceuticals, Inc., Astrazeneca Pharmaceuticals LP, Other. Active years: 2012-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 164 
2 out of 40 
2 out of 834,601 Years Active: 2012-2013
Title: Michalis Nicolaou: Pioneering Innovations in GLP-1 Receptor Agonist Bioassays
Introduction
Michalis Nicolaou is an accomplished inventor based in San Diego, California, whose work has significantly contributed to the field of medicinal chemistry and bioassay development. With four patents to his name, Michalis has dedicated his career to innovating methods for measuring GLP-1 receptor agonist activity, which has implications in diabetes treatment and metabolic research.
Latest Patents
His latest patents focus on the development of cell-based bioassays for assessing GLP-1 receptor agonist activity of test compounds. These patents provide innovative methodologies for quantitatively determining cyclic adenosine monophosphate (cAMP) generated in samples containing GLP-1 receptor agonist compounds, including exendins and GLP-1(7-37) analogs. Notably, these bioassays employ enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays, making it easier to correlate the amount of cAMP with the agnostic activity of GLP-1 receptor agonists like exenatide.
Career Highlights
In his professional journey, Michalis has been associated with prominent companies in the pharmaceutical sector, such as Amylin Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. His experience in these organizations has played a crucial role in shaping his expertise in the development of therapeutic solutions for metabolic diseases.
Collaborations
Throughout his career, Michalis has collaborated with notable scientists, including Frederick Charles Bancroft and John Patrick Herich. These partnerships have fostered a rich exchange of ideas and innovation, contributing to the advancement of research in the field.
Conclusion
Michalis Nicolaou stands out as a pioneering inventor whose work in GLP-1 receptor agonist bioassays has opened new pathways for research in diabetes and metabolic disorders. With a commitment to innovation and collaboration, he continues to make significant contributions to the scientific community and push the boundaries of what is possible in biomedicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile